Well Health Begins Offering Direct To Consumer COVID-19 Antibody Tests In Ontario

Well Health Technologies (TSX: WELL) is getting on the COVID-19 testing trend. The company this morning announced that it has launched direct to consumer online services in the province of Ontario for the sale of COVID-19 antibody tests.

After obtaining a doctors requisition for the antibody test, whih can be acquired via Well Health’s Tia Health platform, patients will be able to purchase the test at a price of $70 each. Once the sample is taken by the patient, they can then have their sample collected at a national laboratory after which they will be able to access the results of the test online.

The national laboratory, whom is not named within the release, has partnered with Well Health’s subsidiary to offer the testing services as well as with online medical consultations for the antibody tests. The test being offered will provide information on the immune response to the virus in previously diagnosed patients, as well as to assist in identifying those of whom have been exposed but not previously diagnosed.

Once the test is taken, the blood sample can be dropped off at one of several collection sites located across the province. Result lead times are currently pegged at three to five days, while results can be provided within 48 hours on a rushed basis.

Well Health Technologies last traded at $6.89 on the TSX.


Information for this briefing was found via Sedar and WELL Health Technologies Corp. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Moon River Moly: The Davidson Moly-Copper-Tungsten PEA

Integra: The DeLamar Heap Leach Feasibility Study

Highlander Silver: The Saviour Of Bear Creek Mining

Recommended

Mercado Minerals Launches Two Phase Geophysical Program At Copalito Project

Altamira Gold Drills 6.1 g/t Gold Over 2.3 Metres At Cajueiro Central, Begins Testing Two New Targets

Related News

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

Well Health Acquires Majority Stake In US-Based Circle Medical For US$14.0 Million

Well Health Technologies (TSX: WELL) this morning announced that it is moving into the US...

Tuesday, September 1, 2020, 08:24:48 AM

Revive Therapeutics Partners With UCSF To Study Bucillamine For Severe COVID-19

Revive Therapeutics (CSE: RVV) this morning had a major announcement, in that it has entered...

Monday, May 3, 2021, 09:24:15 AM

Well Health Secures $10.0 Million Convertible Debt Financing

Well Health Technologies (TSX: WELL) announced this morning that they have secured a convertible debenture...

Tuesday, March 10, 2020, 08:22:29 AM

Pfizer-BioNTech COVID-19 Vaccine Trial For Ages 5-11 Returns Favorable Topline Results

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced this morning the topline results...

Monday, September 20, 2021, 09:17:00 AM